Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and as adjuvant therapy for colon cancer after surgical resection.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Kabi is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. Adjuvant therapy for colon cancer: reduces risk of disease recurrence after curative surgery. Colorectal cancer (in combination therapy): enhances tumor response when used with other cytotoxic agents.

Irinotecan Kabi may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring hospitalization. - Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: rare arrhythmias or ischemic events. - Secondary malignancies: potential long‑term risk of new cancers.

Before initiating Irinotecan Kabi, clinicians should assess patient-specific risk factors and monitor laboratory parameters.

Baseline blood counts: verify adequate neutrophil and platelet levels. Liver function: evaluate hepatic enzymes due to metabolism dependence. Renal function: adjust monitoring if creatinine clearance is impaired. Pregnancy: avoid use; drug is classified Category D and may cause fetal harm. Concomitant medications: review for agents that may exacerbate neutropenia or diarrhea. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Irinotecan Kabi can interact with several drugs that affect its metabolism or toxicity profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - High‑dose irinotecan with other myelosuppressive agents: may cause life‑threatening bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen constipation and abdominal cramping. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Proton pump inhibitors: potential alteration of gastrointestinal absorption. - Diuretics: monitor electrolytes during severe diarrhea. - Herbal supplements affecting liver enzymes: assess for possible interaction.